{"id":534864,"date":"2021-09-07T08:34:49","date_gmt":"2021-09-07T12:34:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/"},"modified":"2021-09-07T08:34:49","modified_gmt":"2021-09-07T12:34:49","slug":"cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/","title":{"rendered":"Cardiff Oncology to Present at Upcoming Investor Conferences in September"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Sept. 7, 2021<\/span> \/PRNewswire\/ —\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that Mark Erlander<\/span>, Ph.D., chief executive officer and James Levine<\/span>, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1×1 investor meetings at the H.C. Wainwright 23rd<\/sup> Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13<\/span> \u2013 15th<\/sup> 2021, and September 27<\/span> \u2013 30th<\/sup> 2021, respectively. <\/p>\n

\n

\n
\n \"Cardiff
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Details on the presentations can be found below. <\/p>\n

\n\n\n\n\n
\n

\n
\n H.C. Wainwright 23rd<\/sup> Annual Global Investment Conference<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Presentation Date:<\/span>\n <\/p>\n<\/td>\n

\n

\n Available on-demand starting at 7:00 AM ET on September 13, 2021<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Webcast Link:<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n https:\/\/journey.ct.events\/view\/50ff15c3-cb28-455a-bf01-6e3b2c0dcfce<\/a>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n\n\n\n\n\n
\n

\n
\n 2021 Cantor Virtual Global Healthcare Conference<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Presentation Date:<\/span>\n <\/p>\n<\/td>\n

\n

\n Thursday, September 30, 2021<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Time:<\/span>\n <\/p>\n<\/td>\n

\n

\n 2:40 \u2013 3:10 PM ET<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Webcast Link:<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n https:\/\/wsw.com\/webcast\/cantor12\/crdf\/2059190<\/a>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

Replays of the presentations will be available by visiting the “Events<\/a>” section of the Cardiff Oncology website after their conclusion and will be archived for 90 days.<\/p>\n

\n About Cardiff Oncology, Inc.
<\/b>Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (“PLK1”) inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase\u00a01b\/2 study of onvansertib in combination with FOLFIRI\/Avastin\u00ae (bevacizumab)\u00a0in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga\u00ae (abiraterone)\/prednisone in metastatic castrate-resistant prostate cancer (mCRPC); and a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). For more information, please visit\u00a0https:\/\/www.cardiffoncology.com<\/a>.\u00a0\u00a0<\/p>\n

\n Cardiff Oncology Contact:
<\/b>
\n Vicki Kelemen<\/span>
\n
Chief Operating Officer
858-952-7652\u00a0
vkelemen@cardiffoncology.com<\/a>\u00a0<\/p>\n

\n Investor Contact:
<\/b>
\n Joyce Allaire<\/span>
\n
LifeSci Advisors
212-915-2569\u00a0
jallaire@lifesciadvisors.com<\/a>\u00a0<\/p>\n

\n Media Contact:
<\/b>
\n Amy Jobe<\/span>, Ph.D.
LifeSci Communications
315-879-8192\u00a0
ajobe@lifescicomms.com<\/a>\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september-301370033.html<\/a><\/p>\n

SOURCE Cardiff Oncology, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that Mark Erlander, Ph.D., chief executive officer and James Levine, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1×1 investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13 \u2013 15th 2021, and September 27 \u2013 30th 2021, respectively. Details on the presentations can be found below. H.C. Wainwright 23rd Annual Global Investment Conference Presentation Date: Available … <\/p>\n

Continue reading “Cardiff Oncology to Present at Upcoming Investor Conferences in September”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534864","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCardiff Oncology to Present at Upcoming Investor Conferences in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology to Present at Upcoming Investor Conferences in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that Mark Erlander, Ph.D., chief executive officer and James Levine, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1×1 investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13 \u2013 15th 2021, and September 27 \u2013 30th 2021, respectively. Details on the presentations can be found below. H.C. Wainwright 23rd Annual Global Investment Conference Presentation Date: Available … Continue reading "Cardiff Oncology to Present at Upcoming Investor Conferences in September"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T12:34:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology to Present at Upcoming Investor Conferences in September\",\"datePublished\":\"2021-09-07T12:34:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/\"},\"wordCount\":416,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/\",\"name\":\"Cardiff Oncology to Present at Upcoming Investor Conferences in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"datePublished\":\"2021-09-07T12:34:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology to Present at Upcoming Investor Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology to Present at Upcoming Investor Conferences in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology to Present at Upcoming Investor Conferences in September - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Sept. 7, 2021 \/PRNewswire\/ —\u00a0Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that Mark Erlander, Ph.D., chief executive officer and James Levine, chief financial officer, of Cardiff Oncology, will present and participate in virtual 1×1 investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference, taking place September 13 \u2013 15th 2021, and September 27 \u2013 30th 2021, respectively. Details on the presentations can be found below. H.C. Wainwright 23rd Annual Global Investment Conference Presentation Date: Available … Continue reading \"Cardiff Oncology to Present at Upcoming Investor Conferences in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T12:34:49+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology to Present at Upcoming Investor Conferences in September","datePublished":"2021-09-07T12:34:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/"},"wordCount":416,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/","name":"Cardiff Oncology to Present at Upcoming Investor Conferences in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","datePublished":"2021-09-07T12:34:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology to Present at Upcoming Investor Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534864"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}